530 related articles for article (PubMed ID: 28233184)
1. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches.
Abraham BP; Ahmed T; Ali T
Handb Exp Pharmacol; 2017; 239():115-146. PubMed ID: 28233184
[TBL] [Abstract][Full Text] [Related]
2. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
Billmeier U; Dieterich W; Neurath MF; Atreya R
World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
[TBL] [Abstract][Full Text] [Related]
4. New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets.
Stefanelli T; Malesci A; Repici A; Vetrano S; Danese S
Curr Drug Targets; 2008 May; 9(5):413-8. PubMed ID: 18473770
[TBL] [Abstract][Full Text] [Related]
5. Which patients with inflammatory bowel disease should receive combination therapy?
Cross RK
Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):715-7. PubMed ID: 25912620
[TBL] [Abstract][Full Text] [Related]
6. [Inflammatory bowel disease: an overview].
Herrlinger K
Med Monatsschr Pharm; 2013 Nov; 36(11):402-8; quiz 409. PubMed ID: 24640117
[TBL] [Abstract][Full Text] [Related]
7. Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?
D'Amico F; Roda G; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):19-24. PubMed ID: 30848193
[TBL] [Abstract][Full Text] [Related]
8. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease.
Andrisani G; Guidi L; Papa A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):890-901. PubMed ID: 22953637
[TBL] [Abstract][Full Text] [Related]
10. [Update: chronic inflammatory bowel disease].
Atreya R; Neumann H; Neurath MF
Dtsch Med Wochenschr; 2015 Nov; 140(23):1762-72. PubMed ID: 26583823
[TBL] [Abstract][Full Text] [Related]
11. Potential role of nutraceutical compounds in inflammatory bowel disease.
Larussa T; Imeneo M; Luzza F
World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632
[TBL] [Abstract][Full Text] [Related]
12. UK guidance opens new therapeutic avenues for patients with moderate-severe ulcerative colitis.
Orchard T
Expert Rev Gastroenterol Hepatol; 2016; 10(3):281-2. PubMed ID: 26651595
[No Abstract] [Full Text] [Related]
13. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
15. Infliximab in ulcerative colitis.
Aberra FN; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of Amino Acids in Inflammatory Bowel Disease.
Liu Y; Wang X; Hu CA
Nutrients; 2017 Aug; 9(9):. PubMed ID: 28832517
[TBL] [Abstract][Full Text] [Related]
17. Surgery for Crohn's disease and anti-TNF agents: the changing scenario.
Sorrentino D; Fogel S; Van den Bogaerde J
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):689-700. PubMed ID: 24161133
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
19. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
[TBL] [Abstract][Full Text] [Related]
20. Personalizing therapy for inflammatory bowel diseases.
Ananthakrishnan AN
Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):549-58. PubMed ID: 23985004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
